Observational studyDigestive diseases and sciences2015
Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.
Observational study in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- The value of platelet-associated parameters as biomarkers in evaluating the disease activity of inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review.Biochemia medica · 2016Pooled it
- Tetrameric assembly disruption impairs CXCL4 chaperon ability for DNA and type I interferon immune amplification.Communications biology · 2026Article
- Platelet activation stimulates macrophages to enhance ulcerative colitis through PF4/CXCR3 signaling.International journal of molecular medicine · 2025Article
- Personalized Treatment for Crohn's Disease: Current Approaches and Future Directions.Clinical and experimental gastroenterology · 2023Review
- High Expression of DC-STAMP Gene Predicts Adverse Outcomes in AML.Frontiers in genetics · 2022Article
- The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease.Inflammatory bowel diseases · 2021Article
- Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.Journal of Crohn's & colitis · 2021Article
- Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores.World journal of gastrointestinal endoscopy · 2020Review
- Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study.Medicine · 2017Article
- Use of blood based biomarkers in the evaluation of Crohn's disease and ulcerative colitis.World journal of gastrointestinal endoscopy · 2015Article
- Current noninvasive modalities in Crohn's disease monitoring.Annals of gastroenterologyReview
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn assessing Crohn's disease (CD) activity, C-reactive protein (CRP) is an important indicator of inflammation; however, it is not necessarily associated with the Crohn's Disease Activity Index (CDAI), particularly in patients with low CRP. Recently, platelet activation factors have been recognized due to their importance in the inflammatory response. In this study, we examined associations between the CDAI and platelet factor 4 (PF-4), β-thromboglobulin (β-TG), and other coagulation and fibrinolysis factors.
aimsWe aimed to find a new marker for evaluating disease activity in patients with CD and low CRP.
methodsNine markers, including CRP, platelet count, white blood cell count, fibrin and fibrinogen degradation product, fibrinogen, thrombin-antithrombin complex, prothrombin fragments 1 + 2, PF-4, and β-TG were evaluated in 47 patients with CD and low CRP (<1.0 mg/dl). Patients were assigned to high or low disease activity groups, CDAI-H (CDAI ≥ 150) and CDAI-L (CDAI < 150), respectively.
resultsCDAI-H exhibited significantly higher PF-4 and β-TG levels than CDAI-L (P < 0.01). Other markers were not significantly different between groups. CDAI was positively correlated with the levels of PF-4 and β-TG (P = 0.0033 and 0.0024; r = 0.4202 and 0.4321, respectively). Receiver operating characteristic curve analyses of PF-4 and β-TG showed high sensitivity (61.9 and 81%, respectively) and specificity (84.7 and 69.2%, respectively) for diagnosing active CD.
conclusionAmong eight potential markers, PF-4 and β-TG were the most highly correlated with CDAI in patients with CD and low CRP. PF-4 and β-TG levels showed promise as new markers for assessing CD in patients with low CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.